Search results (70)
« Back to NewsExogene could be a step closer to AI-powered immunotherapy discovery
11 November 2024
Through UK-Germany Collaborative R&D funding, Exogene is collaborating with the German company Alithea Bio, aiming to accelerate cancer immunotherapy discovery and make it more cost-effective.
Infinitopes to showcase breakthroughs on cancer vaccine development at SITC 2024: Insight into a double-blind, Phase I/IIa clinical trial
8 November 2024
Infinitopes, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimulating protective immune responses, today announces that it will be presenting three posters on its pioneering cancer vaccine discovery and development, including one that has been recognised as a ‘top 100’ poster presentation, at the Society for Immunotherapy of Cancer (SITC) 2024, held in Houston, US, from 6-10th November.
Eterna Biologics: Revolutionising RNA therapeutics
28 August 2024
We are excited to welcome Eterna Biologics, a University of Oxford biotech spinout company with a mission to unleash the full potential of RNA medicines. The company aims to enhance global health by expanding the applicability of RNA-targeting medicine to develop treatment for a wide range of human conditions.
Evolvere Biosciences accepted into the prestigious Y Combinator program
23 August 2024
The team of University of Oxford students is making strides that could transform our approach to antibiotics.
U-Ploid thrilled to join the BioEscalator Community
21 August 2024
U-Ploid Biotechnologies joins the BioEscalator to develop groundbreaking therapeutics that improve egg quality and revolutionise IVF.
RE-AIM Therapeutics: Targeting disease causal cells to cure autoimmunity
18 July 2024
We are delighted to welcome RE-AIM Therapeutics to the BioEscalator community, a start-up focused on developing antibody-based curative therapies for inflammatory disorders, such as psoriasis and inflammatory bowel disease.
The BioEscalator welcomes SiGenex to its growing community
18 July 2024
SiGenex is advancing genomic medicine with its innovative, artificial intelligence-powered in-hospital sequencing platform. The company's technology is designed to transform how hospitals, clinics, and medical centres perform targeted next-generation sequencing (NGS) tests.
Bioarchitech graduates from the BioEscalator: A new chapter for innovative cancer therapy
17 July 2024
Bioarchitech's departure from the BioEscalator marks the beginning of an exciting new phase for the pioneering cancer therapy company, as it transitions to the next stage of its innovative journey.
Granza Bio grabs $7M seed from Felicis and YC to advance delivery of cancer treatments
2 July 2024
In April 2024, the BioEscalator welcomed Granza Bio, a biotech startup focusing on developing novel immunotherapy delivery methods. The company has already attracted investor interest and closed a successful $7.14 million seed funding round led by Felicis and Refactor, with participation from Y Combinator.
MediMabBio's graduation from the BioEscalator: A testament to innovation and growth
5 June 2024
MediMab Biotherapeutics announces its graduation from the BioEscalator. This move represents a major milestone for the company as it relocates to Abingdon Science Park, positioning itself for further expansion and cutting-edge research in immuno-oncology.
Integrated cancer biotech Infinitopes secures £12.8M seed financing to enhance its Precision Immunomics(TM) antigen discovery technologies to target five more cancers
30 April 2024
Funding also supports the start of phase I/IIa study for lead vaccine, ITOP1
Granza Bio: Pioneering personalised and targeted cancer therapeutics
3 April 2024
The BioEscalator is pleased to welcome Granza Bio, a biotech startup founded by two PhD graduates in oncology and immunology from the University of Oxford. Granza Bio is pioneering a new era in cancer therapeutics by developing personalised and targeted cancer treatments using the body's own immune system.
Exogene announces strategic collaboration with Immunocore to engineer T-Cell receptors using artificial intelligence
4 March 2024
Exogene, a pioneer in the use of generative artificial intelligence (AI) for T-cell receptor (TCR) engineering, has entered into a research collaboration with industry leader Immunocore Holdings plc (NASDAQ: IMCR), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases.
Infinitopes has a double victory at the 15th Annual OBN Awards 2023
23 November 2023
The OBN Awards recognise companies that demonstrate outstanding leadership, innovative practices, and significant contributions towards addressing clinical needs at different stages of development.
Hutano Diagnostics acquired by EDX Medical Group
28 September 2023
We are delighted that BioEscalator resident start-up Hutano Diagnostics has announced its acquisition by Cambridge, UK-based EDX Medical Group PLC.
Oxford Silk Phage Technologies wins BioCap 2023 pitch competition
28 September 2023
Despite facing tough competition, Oxford Silk Phage Technologies impressed the judges with its presentation, earning the top spot in the competition.
Alethiomics and Infinitopes shortlisted in the New Startup of the Year category for the Cancer Research Horizons Innovation & Entrepreneurship Awards 2022
5 December 2022
Alethiomics is uncovering new biology to discover and develop life-changing treatments for patients with blood cancer, and Infinitopes is identifying hidden tumour targets, enabling the creation of high-efficiency vaccines.
OSPT selected by INCATEurope as one of the 6 new ventures to receive Stage I support
23 August 2022
This new funding will help OSPT refine its regulatory strategy.
Introducing Oxford Cancer Analytics
21 June 2022
OXcan, short for Oxford Cancer Analytics, uses machine learning techniques combined with cutting-edge liquid biopsy techniques, to search for stage one lung cancer biomarkers.
Introducing Evolvere Biosciences
12 June 2022
A platform to develop biologic therapeutics that outsmart the evolution of antibiotic resistance to save millions of lives.